SEC Form 4 · accession 0001213900-19-003337
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Miriam Kidron
Officer — Chief Scientific Officer · Director
Period of report
Feb 26, 2019
Accepted (ET)
Feb 28, 2019 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.16 | Feb 26, 2019 | A | 104,000 | A | — | Feb 26, 2029 | Common Stock | 104,000 | 104,000 | D |
Explanation of responses
- F1The Stock Option will vest in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.